Pharmaceutical Technology on MSN
Lundbeck’s asedebart receives EC orphan designation in Cushing’s syndrome
Asedebart is a humanised anti-ACTH monoclonal antibody that blocks ACTH binding to melanocortin 2.
Visiongain has published a new report on Adrenocorticotropic Hormone (ACTH) Market Report 2021-2031: Forecasts By Type (ABQ-565, BIM-23B065, Corticotropin, Others, By Product (Natural, and Synthetic), ...
Lundbeck today announced that the European Commission has granted orphan designation to asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of ...
THE first part of this communication is a detailed presentation of two patients who sustained cold injuries and who were treated with pituitary adrenocorticotrophic hormone. The dosage of the hormone ...
F.J., a 35-year-old Negro housewife, first entered Vanderbilt University Hospital on February 8, 1964, with the chief complaints of nervousness and weight loss. She had noted excessive facial hair ...
Athletes and the general population alike train to promote health and physical fitness. With repeated exposure to the minimal stress of exercise, the body adapts. Researchers at the University of ...
The European Commission has granted orphan designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of Cushing's syndrome of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results